AKT Signaling in ERBB2-amplified Breast Cancer

Pharmacology and Therapeutics - United Kingdom
doi 10.1016/j.pharmthera.2015.11.013
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Elsevier BV

Related search

Strong EGFR Signaling in Cell Line Models of ERBB2-amplified Breast Cancer Attenuates Response Towards ERBB2-targeting Drugs

Oncogenesis
Cancer ResearchMolecular Biology
2012English

An Insertion Mutation of ERBB2 Enhances Breast Cancer Cell Growth and Confers Resistance to Lapatinib Through AKT Signaling Pathway

Biology Open
BiochemistryAgriculturalGeneticsMolecular BiologyBiological Sciences
2020English

Functional Redundancy Between Β1 and Β3 Integrin in Activating the IR/Akt/mTORC1 Signaling Axis to Promote ErbB2-Driven Breast Cancer

Cell Reports
BiochemistryGeneticsMolecular Biology
2019English

Akt Rescue in Cardiomyocytes but Not Breast Cancer Cells After Doxorubicin and Anti-erbB2 Treatment

2005English

Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Cancer Research
Cancer ResearchOncology
2011English

Pristimerin Overcomes Adriamycin Resistance in Breast Cancer Cells Through Suppressing Akt Signaling

Oncology Letters
Cancer ResearchOncology
2016English

Wedelolactone Inhibits Breast Cancer-Induced Osteoclastogenesis by Decreasing Akt/mTOR Signaling

International Journal of Oncology
Cancer ResearchOncology
2014English

Downregulation of Notch Pathway by a -Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model

Cancer Research
Cancer ResearchOncology
2010English

FOXP1 Regulation via the PI3K/Akt/p70S6K Signaling Pathway in Breast Cancer Cells

Oncology Letters
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy